Uncovering the Clinical Research Propelling ILD Drug Development Forwards in 2022 & Beyond

8:30 am Registration & Networking

8:55 am Chair’s Opening Remarks

9:00 am Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials

  • Craig Conoscenti Medical Expert ILD Respiratory Clinical Development & Medical Affairs, Boehringer Ingelheim


• Looking at previous clinical studies to understand primary, secondary
and exploratory outcomes and how these may help to better
characterize the progressive phenotype
• Looking at response rates of differing ILD diagnosis’ within previous
clinical trials in patients with the progressive phenotype
• Investigating previous exploratory/new composite outcomes and
understanding how to use them in new clinical trails given the existing
standard of care

9:30 am Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution

  • Eric White Senior Clinical Program Lead, Boehringer Ingelheim


  • Discussing the applicability of extrapolating data from IPF to other
  • Defining which ILD states are most believable to lump together with IPF
  • Evaluating criteria used to lump and split, spotlight on CT imaging,
    clinical characteristics, lung limited disease and more

10:00 am Uncovering Trial Design Considerations in Sarcoid

  • Majd Mouded Executive Director for BioMedical Research, Novartis


  • Investigating the complexities of Sarcoid trial design
  • Examining CMK-389 in sarcoid
  •  Gaining a high level overview of clinical trial design and execution

10:30 am Speed Networking

11:00 am Morning Break & Networking

Uncovering Emerging ILD Therapeutic Approaches

11:30 am Developing Therapies for Rare Lung Diseases: ILD 101


• Discovering VP01 (C21) for interstitial lung disease
• Outlining our therapeutic approach for interstitial lung disease – how we
strategized our ILD drug development
• Exploring challenges associated with ILD drug development and
learning how to overcome them

12:00 pm Lunch Break & Networking

1:00 pm Single vs Multiple Benefit Drugs for ILD

  • Matt Bradley Founder, Chairman, President, & Chief Technical Officer, SAJE Pharma


• Is it better to have a single target with multiple benefits?
• Investigating GSNOR inhibition
• Exploring single targets with no known safety issues

1:30 pm Update on Inhaled Drug Delivery: The Application of Anticalins in the Treatment of Lung Fibrosis

  • Vanessa Neins Senior Scientist - Biology Lead Respiratory, Pieris Pharmaceuticals


  • Highlighting the benefits of local intervention via inhalation versus
    systemic administration
  • Inhaled Anticalin antagonists for respiratory disease
  • Reviewing the development of PRS-220, a potential best-in-class,
    inhaled CTGF inhibitor for the treatment of IPF

Analyzing & Scrutinizing ILD Mechanisms

2:00 pm Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development

  • Shannon Turley Vice President of Cancer Immunology Discovery, Genentech


  • Investigating fibroblasts as drivers of fibrotic indications for lung diseases
  • Exploring tools/pharmacologic agents to target fibrotic pathways/
    inflammatory pathways
  • Understanding the similarities and differences between cellular interactions
    and molecular pathways in cancer and ILDs

2:30 pm The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis


• Macrophages play a key role in the pathogenesis of IPF, but the role of
macrophage metabolism is not well understood.
• We have found that macrophages in IPF are metabolically reprogrammed with
alterations in iron (Allden et al, AJRCCM 2019), glycolysis (McErlean et al, AJRCCM
20201) and TCA cycle (Ogger et al, Science immunology 2020) pathways
• Macrophage metabolism therefore represents an exciting therapeutic target in IPF

3:00 pm Afternoon Break & Networking

Strategizing New Target Identification for Novel Therapies 101

4:00 pm Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis


• Understand the rationale for ROCK2 in lung fibrosis
• Assess the development of RXC007, a highly selective ROCK2 inhibitor
• Review preclinical studies in rodents and in Human Precision Cut Lung Slices

4:30 pm Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury

  • Glenn Rosen Chief Scientific Officer, Optikira & Biomotiv


  • Examine interactions between injury repair cascade and fibrosis in IPF/ILD
  • Evaluate druggability of pathways which target lung epithelial injury, repair
    and regeneration
  • How to kickstart your ILD drug discovery program

5:00 pm Chair’s Closing Remarks

5:05 pm End of Conference Day Two